Experimental drug targets tough cancers in early trial
NCT ID NCT06098651
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 28 times
Summary
This early-phase study tested an experimental drug called DCR-STAT3 in 26 adults with advanced solid tumors that no longer responded to standard treatments. The main goal was to check the drug's safety and how the body processes it. Researchers gave increasing doses to find the best and safest level.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Next Oncology
Dallas, Texas, 75039, United States
-
Next Oncology
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.